Citations

Clear

107 citation(s) found for "Scheithauer, Bernd".

Double Adenomas of the Pituitary
Kontogeorgos, George , Scheithauer, Bernd W., Kovács, Kálmán, Lloyd, Ricardo V., Smyth, Harley S., Rologis, D.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 31 | Issue: 5 | Pages: 840-853

10.1227/00006123-199211000-00003 | PMID 1331847 Get It

Immunohistochemical Expression of Pituitary Tumor Transforming Gene (PTTG) in Pituitary Adenomas: A Correlative Study of Tumor Subtypes
Salehi, Fateme , Kovács, Kálmán, Scheithauer, Bernd W., Cantelmi, David , Horváth, Éva , Lloyd, Ricardo V., Cusimano, Michael D.

Mayo Clinic

International Journal of Surgical Pathology | January 27, 2010 | Volume: 18 | Issue: 1 | Pages: 5-13

10.1177/1066896909356105 | PMID 20106827 Get It

Objective. We investigated the correlation between immunohistochemical expression of the pituitary tumor transforming gene (PTTG) and pituitary adenoma subtype. Methods. Pituitary adenomas (n = 89) were stained for PTTG using the streptavidin—biotin—peroxidase complex method and a monoclonal PTTG antibody. Results. PTTG staining was found to be cytoplasmic with a pronounced paranuclear expression pattern. Reactivity was highest in growth hormone (GH) adenomas as compared with other tumors, including prolactin (PRL), follicle-stimulating hormone/luteinizing hormone/α subunit, as well as adrenocorticotrophic hormone—secreting adenomas. PRL adenomas exhibited the lowest expression levels. Among GH adenomas, untreated tumors demonstrated significantly higher PTTG levels than octreotide-treated examples. Although dopamine agonist—treated PRL adenomas tended to show lower expression levels, statistical significance was not reached. Conclusions. Our finding that PTTG was differentially expressed in pituitary adenoma subtypes suggests a cell-specific function for PTTG. Moreover, treatment of GH adenomas with somatostatin analogues lowered PTTG expression. Further investigation into mechanisms mediating cell-specific expression of PTTG is warranted.
Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis Type 2
Carlson, Matthew L. , Babovic‐Vuksanovic, Dusica , Messiaen, Ludwine , Scheithauer, Bernd W., Neff, Brian A., Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | July 3, 2009 | Volume: 112 | Issue: 1 | Pages: 81-87

10.3171/2009.6.jns09105 | PMID 19575577 Get It

Neurofibromatosis Type 2 (NF2) is a rare autosomal dominant disorder characterized by the development of benign tumors of the peripheral nervous system and the CNS, including schwannomas, meningiomas, and ependymomas. The gene responsible for the development of NF2 acts as a tumor suppressor gene. Stereotactic radiotherapy (SRT) or single-fraction stereotactic radiosurgery has been increasingly used in the past decades to treat benign tumors in patients with NF2. These radiotherapy methods are less invasive and can be potentially used to treat multiple tumors in a single session. The risk of inducing malignancy is unclear. Few reports exist of malignant peripheral nerve sheath tumors, meningiomas, or ependymomas occurring after SRT or stereotactic radiosurgery in patients with NF2. The authors present the first documented case of rhabdomyosarcoma following SRT for multiple NF2-associated schwannomas. Compared with patients with sporadic tumors, NF2 patients having a germline tumor suppressor gene defect may be more prone to secondary malignancies after treatment involving radiation therapy.
Multinodular/plexiform (multifascicular) schwannomas of major peripheral nerves: an underrecognized part of the spectrum of schwannomas
Hébert-Blouin, Marie-Noëlle, Amrami, Kimberly K. , Scheithauer, Bernd W., Spinner, Robert J. , Hébert‐Blouin, Marie‐Noëlle

Mayo Clinic

Journal of Neurosurgery | June 5, 2009 | Volume: 112 | Issue: 2 | Pages: 372-382

10.3171/2009.5.jns09244 | PMID 19499977 Get It

Object In clinical practice, schwannomas are among the most common types of nerve sheath tumors. Their clinical presentation, imaging characteristics, and operative features are well known. Over the past 20 years, clinical outcomes have improved due to resection of these tumors at a fascicular level. Despite these advances, a subgroup of patients with schwannomas is associated with a disappointing neurological outcome following resection. The purpose of this study was to correlate the imaging and histological features in this group of patients with more anatomically complex forms of schwannomas. Methods In a retrospective review performed at their institution over a 10-year period, the authors found a subgroup of patients with complex multinodular/plexiform schwannomas affecting major peripheral nerves. Eleven patients were identified, and the clinical, imaging, and pathological features of their disease were reviewed. Results The clinical presentation of multinodular/plexiform schwannomas of major peripheral nerves may be similar to that of conventional schwannomas, but their imaging features, operative appearance, and outcomes differ. Conclusions Preoperatively and intraoperatively, the distinguishing features of multinodular/plexiform schwannomas of major peripheral nerves may be subtle and can easily go unrecognized, thus explaining the often suboptimal surgical results. Familiarity with the imaging and operative features of multinodular/plexiform schwannomas will no doubt alter treatment approaches and improve neurological function in this subgroup of patients.
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Jaeckle, Kurt A. , Maurer, Matthew J. , Ames, Matthew M. , Hardwick, James S., Reilly, John F. , Loboda, Andrey , Nebozhyn, Michael , Fantin, Valeria R. , Richon, Victoria M., Scheithauer, Bernd W., Flynn, Patrick J. , Moore, Dennis F., Buckner, Jan C. , Galanis, Evanthia , Reid, Joel M. , Giannini, Caterina , Zwiebel, James A. , Maurer, Matthew

Mayo Clinic

Journal of Clinical Oncology | March 23, 2009 | Volume: 27 | Issue: 12 | Pages: 2052-2058

10.1200/jco.2008.19.0694 | PMID 19307505 Get It

Purpose Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM). Patients and Methods Patients with recurrent GBM who had received one or fewer chemotherapy regimens for progressive disease were eligible. Vorinostat was administered at a dose of 200 mg orally twice a day for 14 days, followed by a 7-day rest period. Results A total of 66 patients were treated. Grade 3 or worse nonhematologic toxicity occurred in 26% of patients and consisted mainly of fatigue (17%), dehydration (6%), and hypernatremia (5%); grade 3 or worse hematologic toxicity occurred in 26% of patients and consisted mainly of thrombocytopenia (22%). Pharmacokinetic analysis showed lower vorinostat maximum concentration and area under the curve (0 to 24 hours) values in patients treated with enzyme-inducing anticonvulsants, although this did not reach statistical significance. The trial met the prospectively defined primary efficacy end point, with nine of the first 52 patients being progression-free at 6 months. Median overall survival from study entry was 5.7 months (range, 0.7 to 28+ months). Immunohistochemical analysis performed in paired baseline and post-vorinostat treatment samples in a separate surgical subgroup of five patients with recurrent GBM showed post treatment increase in acetylation of histones H2B and H4 (four of five patients) and of histone H3 (three of five patients). Microarray RNA analysis in the same samples showed changes in genes regulated by vorinostat, such as upregulation of E-cadherin (P = .02). Conclusion Vorinostat monotherapy is well tolerated in patients with recurrent GBM and has modest single-agent activity. Histone acetylation analysis and RNA expression profiling indicate that vorinostat in this dose and schedule affects target pathways in GBM. Additional testing of vorinostat in combination regimens is warranted.
The Significance of Atypia and Histologic Malignancy in Pilocytic Astrocytoma of the Cerebellum: A Clinicopathologic and Flow Cytometric Study
Tomlinson, Francis H., Scheithauer, Bernd W., Hayostek, Cherie J., Parisi, Joseph E. , Meyer, Fredric B. , Shaw, Edward G. , Weiland, Timothy L., Katzmann, Jerry A., Jack, Clifford R. , Jack, Clifford R

Mayo Clinic

Journal of Child Neurology | December 24, 2008 | Volume: 9 | Issue: 3 | Pages: 301-310

10.1177/088307389400900317 | PMID 7930411 Get It

Biologically malignant pilocytic astrocytomas are rare. Precise morphologic criteria permitting their identification and clinically meaningful distinction from more ordinary pilocytic astrocytomas have not been developed. The histologic grading schemes applied to fibrillary astrocytomas—ones based on nuclear atypia, increased cellularity, mitotic activity, endothelial proliferation, and necrosis—are thought not to correlate with prognosis in pilocytic astrocytomas. Nonetheless, these features were systematically sought in 107 cerebellar pilocytic astrocytomas, four of which were histologically malignant. The clinical, morphologic, and flow cytometric features of these cases were studied. The incidence of histologic malignancy occurring spontaneously in otherwise typical pilocytic astrocytomas was 0.9%; that occurring after radiation was 1.8%. The four histologically malignant tumors occurred in two males and two females, ages 6 to 18 years. All showed increased mitotic activity (three to five mitoses per high-power microscopic field [250×]). Endothelial proliferation and necrosis were present in three and two cases each. DNA ploidy analysis showed the spontaneously occurring malignant-appearing tumors to be aneuploid, whereas both previously radiated tumors were tetraploid; 5% to 11% of cells were in S phase. The appearance of histologic malignancy in pilocytic astrocytoma is rare and less reliably correlated with prognosis than in patients with fibrillary astrocytomas. Essential features of such tumors include a high mitotic index and perhaps a high percentage of cells in S phase. (J Child Neurol 1994;9:301-310).
Topical Review Article: Medulloblastoma: II. A Pathobiologic Overview
Tomlinson, Frank H., Scheithauer, Bernd W., Jenkins, Robert B.

Mayo Clinic

Journal of Child Neurology | December 24, 2008 | Volume: 7 | Issue: 3 | Pages: 240-252

10.1177/088307389200700302 | PMID 1634745 Get It

The pathobiology of medulloblastoma is reviewed in light of emerging data regarding its immunocytochemical and cytobiologic, as well as molecular biologic, characteristics. The nature of the lesion, particularly its nosologic relation to primitive neuroectodermal tumor, is discussed, as is its place in the World Health Organization classification of tumors of the central nervous system. ( J Child Neurol 1992;7:240-252).
Topical Review Article: Medulloblastoma: I. Clinical, Diagnostic, and Therapeutic Overview
Tomlinson, Frank H., Scheithauer, Bernd W., Meyer, Fredric B. , Smithson, William A., Shaw, Edward G. , Miller, Gary M. , Groover, Robert V.

Mayo Clinic

Journal of Child Neurology | December 24, 2008 | Volume: 7 | Issue: 2 | Pages: 142-155

10.1177/088307389200700203 | PMID 1573231 Get It

Medulloblastoma, the most common embryonal tumor of the central nervous system, affects both children and adults. It poses a significant therapeutic challenge in that age-dependent differences exist, not only in their pathobiology, but in the efficacy of chemotherapy and radiotherapy. This is particularly the case in very young children, whose still developing nervous system exhibits a low tolerance to radiotherapy. We review the epidemiology, clinical presentation, radiologic features, and current therapeutic concepts relative to this unique neoplasm. Efforts are made to highlight clinical controversies. ( J Child Neurol 1992;7:142-155).
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Brown, Paul D. , Jaeckle, Kurt A. , Uhm, Joon H. , Geoffroy, Francois J., Arusell, Robert M., Kitange, Gaspar J. , Jenkins, Robert B. , Kugler, John W., Morton, Roscoe F., Rowland, Kendrith M. , Yong, William H. , Scheithauer, Bernd W., Schiff, David , Buckner, Jan C. , Krishnan, Sunil , Sarkaria, Jann N. , Wu, Wenting , Mischel, Paul S. , Giannini, Caterina

Mayo Clinic

Journal of Clinical Oncology | October 28, 2008 | Volume: 26 | Issue: 34 | Pages: 5603-5609

10.1200/jco.2008.18.0612 | PMID 18955445 Get It

Purpose Epidermal growth factor receptor (EGFR) amplification in glioblastoma multiforme (GBM) is a common occurrence and is associated with treatment resistance. Erlotinib, a selective EGFR inhibitor, was combined with temozolomide (TMZ) and radiotherapy (RT) in a phase I/II trial. Patients and Methods Adults not taking enzyme-inducing anticonvulsants after resection or biopsy of GBM were treated with erlotinib (150 mg daily) until progression. Erlotinib was delivered alone for 1 week, then concurrently with TMZ (75 mg mg/m2 daily) and RT (60 Gy), and finally, concurrently with up to six cycles of adjuvant TMZ (200 mg/m2 daily for 5 days every 28 days). The primary end point was survival at 1 year. Results Ninety-seven eligible patients were accrued with a median follow-up time of 22.2 months. By definition, the primary end point was successfully met with a median survival time of 15.3 months. However, there was no sign of benefit in overall survival when comparing N0177 with the RT/TMZ arm of the European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada trial 26981/22981 (recursive partitioning analysis [RPA] class III, 19 v 21 months; RPA class IV, 16 v 16 months; RPA class V, 8 v 10 months, respectively). Presence of diarrhea, rash, and EGFRvIII, p53, phosphatase and tensin homolog (PTEN), combination EGFR and PTEN, and EGFR amplification status were not predictive (P > .05) of survival. Conclusion Although the primary end point was successfully met using nitrosourea-based (pre-TMZ) chemotherapy era historic controls, there was no sign of benefit compared with TMZ era controls. Analyses of molecular subsets did not reveal cohorts of patients sensitive to erlotinib. TMZ chemotherapy combined with RT resulted in improved outcomes compared with historical controls who received nitrosourea-based chemotherapies.
Clinicopathological Characteristics of Atypical Teratoid/Rhabdoid Tumor
Oka, Hidehiro, Scheithauer, Bernd W.

Mayo Clinic

Neurologia medico-chirurgica | March 26, 2008 | Volume: 39 | Issue: 7 | Pages: 510-518

10.2176/nmc.39.510 | PMID 10437379 Get It